• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

糖肽PV - PS A1免疫原引发CD4 +和CD8 +反应。

The Glycopeptide PV-PS A1 Immunogen Elicits Both CD4+ and CD8+ Responses.

作者信息

Nishat Sharmeen, Hossain Md Kamal, Valentin Geraud, Hossain Farzana, Gamage Shanika, Wall Katherine A, Andreana Peter R

机构信息

Department of Chemistry, Bangladesh University of Engineering and Technology (BUET), Dhaka 1000, Bangladesh.

Department of Medicinal and Biological Chemistry, College of Pharmacy and Pharmaceutical Sciences, The University of Toledo, 2801 West Bancroft Street, Toledo, OH 43606, USA.

出版信息

Vaccines (Basel). 2024 Dec 6;12(12):1375. doi: 10.3390/vaccines12121375.

DOI:10.3390/vaccines12121375
PMID:39772036
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11680115/
Abstract

BACKGROUND/OBJECTIVES: The MHCII-dependent, CD4+ T-cell zwitterionic polysaccharide PS A1 has been investigated as a promising carrier for vaccine development because it can induce an MHCII-dependent CD4+ response towards a variety of tumor-associated carbohydrate antigens (TACAs). However, PS A1 cannot elicit cytotoxic T lymphocytes through MHCI, which may or may not hamper its potential clinical use in cancer, infectious and viral vaccine development. This paper addresses PS A1 MHCI independence through the introduction of an MHCI epitope, the poliovirus (PV) peptide, to establish an MHCI- and MHCII-dependent vaccine.

METHODS

We synthesized a glycopeptide construct targeting the Thomsen-nouveau TACA (Tn-PV-PS A1) and a control Tn-PV peptide. C57BL/6 mice were immunized with both constructs, and the resulting T-cells were extracted from spleens.

RESULTS

Through cell proliferation assays, we show that Tn-PV-PS A1 elicits a robust CD4+ and CD8+ immune response. The resulting cytotoxic T lymphocytes are specific towards Tn-PV and trigger cell lysis of Tn-expressing EL4 cells.

CONCLUSIONS

This study confirms PV-PS A1 as a robust MHCI- and MHCII-dependent carrier. This is the first report of MHCI dependence in a zwitterionic polysaccharide.

摘要

背景/目的:依赖MHCII的CD4+ T细胞两性离子多糖PSA1已被研究作为一种有前景的疫苗开发载体,因为它可以诱导针对多种肿瘤相关碳水化合物抗原(TACA)的依赖MHCII的CD4+反应。然而,PSA1不能通过MHC I引发细胞毒性T淋巴细胞,这可能会也可能不会妨碍其在癌症、传染病和病毒疫苗开发中的潜在临床应用。本文通过引入MHC I表位脊髓灰质炎病毒(PV)肽来解决PSA1对MHC I的独立性问题,以建立一种依赖MHC I和MHCII的疫苗。

方法

我们合成了一种靶向汤姆森-诺沃TACA(Tn-PV-PSA1)的糖肽构建体和一个对照Tn-PV肽。用这两种构建体免疫C57BL/6小鼠,并从脾脏中提取产生的T细胞。

结果

通过细胞增殖试验,我们表明Tn-PV-PSA1引发了强大的CD4+和CD8+免疫反应。产生的细胞毒性T淋巴细胞对Tn-PV具有特异性,并触发表达Tn的EL4细胞的细胞裂解。

结论

本研究证实PV-PSA1是一种强大的依赖MHC I和MHCII的载体。这是关于两性离子多糖中MHC I依赖性的首次报道。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/64ce/11680115/e041aea2911a/vaccines-12-01375-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/64ce/11680115/1dd13cf5c92d/vaccines-12-01375-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/64ce/11680115/b9a2b6728d71/vaccines-12-01375-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/64ce/11680115/e041aea2911a/vaccines-12-01375-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/64ce/11680115/1dd13cf5c92d/vaccines-12-01375-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/64ce/11680115/b9a2b6728d71/vaccines-12-01375-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/64ce/11680115/e041aea2911a/vaccines-12-01375-g003.jpg

相似文献

1
The Glycopeptide PV-PS A1 Immunogen Elicits Both CD4+ and CD8+ Responses.糖肽PV - PS A1免疫原引发CD4 +和CD8 +反应。
Vaccines (Basel). 2024 Dec 6;12(12):1375. doi: 10.3390/vaccines12121375.
2
Immunological response from an entirely carbohydrate antigen: design of synthetic vaccines based on Tn-PS A1 conjugates.完全由碳水化合物抗原引发的免疫反应:基于Tn-PS A1缀合物的合成疫苗设计。
J Am Chem Soc. 2009 Jul 22;131(28):9622-3. doi: 10.1021/ja902607a.
3
Elucidating Structural Features of an Entirely Carbohydrate Cancer Vaccine Construct Employing Circular Dichroism and Fluorescent Labeling.利用圆二色性和荧光标记阐明完全由碳水化合物组成的癌症疫苗构建体的结构特征。
Medchemcomm. 2014 Aug 1;5(8):1143-1149. doi: 10.1039/C4MD00038B.
4
Synthesis of glycoimmunogen Tn-Thr-PS A1 hydrazone bond and stability optimization of PS A1 monosaccharide mimics under vaccine development conditions.糖免疫原Tn-Thr-PS A1腙键的合成及疫苗开发条件下PS A1单糖模拟物的稳定性优化
J Carbohydr Chem. 2020;39(2-3):107-129. doi: 10.1080/07328303.2019.1709975. Epub 2020 Feb 3.
5
The entirely carbohydrate immunogen Tn-PS A1 induces a cancer cell selective immune response and cytokine IL-17.完全碳水化合物免疫原 Tn-PS A1 可诱导癌细胞选择性免疫反应和细胞因子 IL-17。
Cancer Immunol Immunother. 2012 Apr;61(4):581-5. doi: 10.1007/s00262-012-1205-9.
6
Sialyl-Tn Polysaccharide A1 as an Entirely Carbohydrate Immunogen: Synthesis and Immunological Evaluation.唾液酸化 Tn 多糖 A1 作为一种全碳水化合物免疫原:合成与免疫学评价。
J Am Chem Soc. 2016 Nov 2;138(43):14264-14272. doi: 10.1021/jacs.6b05675. Epub 2016 Oct 21.
7
Enhanced Immune Response Against the Thomsen-Friedenreich Tumor Antigen Using a Bivalent Entirely Carbohydrate Conjugate.使用双价全碳水化合物缀合物增强针对 Thomsen-Friedenreich 肿瘤抗原的免疫应答。
Molecules. 2020 Mar 13;25(6):1319. doi: 10.3390/molecules25061319.
8
Production of a mouse monoclonal IgM antibody that targets the carbohydrate Thomsen-nouveau cancer antigen resulting in in vivo and in vitro tumor killing.生产一种针对碳水化合物 Thomsen-nouveau 癌抗原的鼠源单克隆 IgM 抗体,导致体内和体外肿瘤杀伤。
Cancer Immunol Immunother. 2018 Sep;67(9):1437-1447. doi: 10.1007/s00262-018-2206-0. Epub 2018 Jul 20.
9
Functional characterization of MHC class II-restricted CD8+CD4- and CD8-CD4- T cell responses to infection in CD4-/- mice.MHC II类分子限制性CD8⁺CD4⁻和CD8⁻CD4⁻T细胞对CD4⁻/⁻小鼠感染反应的功能特性
J Immunol. 2004 Aug 15;173(4):2494-9. doi: 10.4049/jimmunol.173.4.2494.
10
CD8+ but not CD4+ T cells require cognate interactions with target tissues to mediate GVHD across only minor H antigens, whereas both CD4+ and CD8+ T cells require direct leukemic contact to mediate GVL.仅针对微小组织相容性抗原介导移植物抗宿主病(GVHD)时,CD8⁺而非CD4⁺T细胞需要与靶组织进行同源相互作用,而CD4⁺和CD8⁺T细胞介导移植物抗白血病效应(GVL)均需要与白血病细胞直接接触。
Blood. 2008 Apr 1;111(7):3884-92. doi: 10.1182/blood-2007-11-125294. Epub 2008 Jan 25.

本文引用的文献

1
Attempt to Substitute the Oncotype DX Breast Recurrence Score Test by Histopathological Factors and MUC1 Protein Expression.尝试通过组织病理学因素和MUC1蛋白表达替代Oncotype DX乳腺复发评分检测。
Cancer Diagn Progn. 2024 Jul 3;4(4):464-469. doi: 10.21873/cdp.10349. eCollection 2024 Jul-Aug.
2
MUC1-EGFR crosstalk with IL-6 by activating NF-κB and MAPK pathways to regulate the stemness and paclitaxel-resistance of lung adenocarcinoma.MUC1-EGFR 与 IL-6 通过激活 NF-κB 和 MAPK 通路相互作用,调节肺腺癌的干性和紫杉醇耐药性。
Ann Med. 2024 Dec;56(1):2313671. doi: 10.1080/07853890.2024.2313671. Epub 2024 Feb 7.
3
Canonical and truncated transglutaminase-2 regulate mucin-1 expression and androgen independency in prostate cancer cell lines.
经典型和截短型转谷氨酰胺酶-2 调节前列腺癌细胞系中黏蛋白-1 的表达和雄激素非依赖性。
Cell Death Dis. 2023 May 9;14(5):317. doi: 10.1038/s41419-023-05818-9.
4
Development of synthetic, self-adjuvanting, and self-assembling anticancer vaccines based on a minimal saponin adjuvant and the tumor-associated MUC1 antigen.基于最小化皂苷佐剂和肿瘤相关MUC1抗原的合成、自佐剂化和自组装抗癌疫苗的研发。
Chem Sci. 2023 Mar 1;14(13):3501-3513. doi: 10.1039/d2sc05639a. eCollection 2023 Mar 29.
5
A combination of immunohistochemical markers, MUC1, MUC5AC, PAX8 and growth pattern for characterization of mucinous neoplasm of the ovary.联合应用免疫组化标志物 MUC1、MUC5AC、PAX8 及生长方式对卵巢黏液性肿瘤进行特征性描述。
Int J Gynecol Cancer. 2022 May 3;32(5):662-668. doi: 10.1136/ijgc-2021-003104.
6
Long Term Impact of Conjugate Vaccines on Meningitis: Narrative Review.结合疫苗对脑膜炎的长期影响:叙述性综述
Microorganisms. 2021 Apr 21;9(5):886. doi: 10.3390/microorganisms9050886.
7
Virus-like particles: preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers.病毒样颗粒:制备、免疫原性及其作为纳米疫苗和药物纳米载体的作用。
J Nanobiotechnology. 2021 Feb 25;19(1):59. doi: 10.1186/s12951-021-00806-7.
8
Development of an adjuvanted nanoparticle vaccine against influenza virus, an in vitro study.抗流感病毒佐剂纳米颗粒疫苗的研制:体外研究。
PLoS One. 2020 Aug 6;15(8):e0237218. doi: 10.1371/journal.pone.0237218. eCollection 2020.
9
MUC1-C drives stemness in progression of colitis to colorectal cancer.黏蛋白 1 羧基端糖蛋白驱动结肠炎向结直肠癌的进展中的干细胞特性。
JCI Insight. 2020 Jun 18;5(12):137112. doi: 10.1172/jci.insight.137112.
10
Development of Next Generation Vaccines Conferring Broad Protection.具有广泛保护作用的下一代疫苗的研发。
Vaccines (Basel). 2020 Mar 17;8(1):132. doi: 10.3390/vaccines8010132.